WestlakeVillageBioPartners
@BioWestlake
Followers
133
Following
81
Media
26
Statuses
68
Helping entrepreneurs in life sciences do things that have never been done before.
Los Angeles
Joined October 2019
Welcome to Patricia Turney, who has joined Westlake-backed ACELYRIN as Chief Technical Operations Officer. Patricia is an accomplished supply chain, manufacturing, and QC leader who will support the advancement of ACELYRIN’s programs through late-stage clinical trials.
0
1
1
Congratulations Westlake-backed @CapsidaBio and KateTx on their strategic partnership to leverage Capsida's expertise and #AAV manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Read more:
0
1
4
Congratulations to Mira Chaurushiya, Ph.D., and David Allison, Ph.D. These leaders, alongside Beth Seidenberg, M.D., will manage our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies. Read more: https://t.co/oAnEU9MroM
0
0
0
Beth Seidenberg on the launch of our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies in the #LosAngeles region and beyond. Read more: https://t.co/oAnEU9MroM
#venturecapital #biotechinvesting
0
0
1
Congratulations to our next generation of leaders: Mira Chaurushiya, Ph.D., and David Allison, Ph.D., joining Beth Seidenberg, M.D. as managing directors. These leaders will work together to build great companies from the ground up. Read more: https://t.co/SiockKdjjG
0
0
2
The new fund will be managed by founding managing director Beth Seidenberg, M.D., and managing directors Mira Chaurushiya, Ph.D., and David Allison, Ph.D.
0
0
0
We’re thrilled to announce the launch of our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies in the #LosAngeles region and beyond. Read more: https://t.co/SiockKdjjG
1
2
2
Westlake-backed Kate Therapeutics debuts with $51 million Series A to develop next-generation genetic medicines to treat muscle and heart diseases. #genetherapy Read the press release:
0
0
3
We're thrilled to share that Mira Chaurushiya, Managing Director at Westlake Village BioPartners, has been named one of Endpoints News' LGBTQ+ biopharma leaders for 2023. Congratulations, Mira! Read the article: https://t.co/SHqd95IMNs
#pridemonth #biopharma
endpoints.news
To intro last year’s inaugural Endpoints News feature on LGBTQ+ leaders in biopharma, I wrote about the movement and progress being made for this community. I feel I might ...
0
0
1
Congratulations to Westlake-backed ACELYRIN, INC. for appointing Henry Gosebruch to the Company's board of directors. You can read the news release here: https://t.co/jkIIeO3Sv1
0
0
1
Congratulations to Westlake-backed @ArsenalBio on their collaboration with @thermofisher Scientific to support clinical manufacturing of autologous T-cell therapies. Read the press release: https://t.co/38Hvv4nj3z
https://t.co/gItrLyEobm
0
0
0
Don’t miss Sean Harper’s panel at the Greater Conejo Valley Chamber Regional Economic Forecast on March 10, and keynote by Matthew Fienup, Executive Director of CERF, California Lutheran University. For more information and to register, visit https://t.co/HwxUUzUFYI.
0
0
2
Congratulations to Westlake-backed Neuron23 on initiating dosing in a Phase 1 clinical trial of NEU-723.
Today, Neuron23 announced that we’ve initiated dosing in a Phase 1 clinical trial of NEU-723 – a highly potent and selective brain penetrant LRRK2 inhibitor – for the treatment of Parkinson’s disease. Read more: https://t.co/LcK46WKjkI
#parkinsonsdisease #LRRK2
0
0
1
Westlake-backed @ArsenalBio announced its first patient has been dosed in a Phase 1 clinical trial of AB-1015, in development as a treatment for ovarian cancer. ArsenalBio will provide more details January 10 at the J.P. Morgan 41st Annual Healthcare Conference.
The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development:
0
0
4
We’re thrilled to announce the launch of Westlake-backed Dantari Inc., with $47 million Series A. Proceeds from the financing will support advancement of Dantari’s best-in-class next-gen targeted therapeutics for cancers and other diseases. Learn more:
1
2
7
Today, Weslake-backed ACELYRIN, INC. announced the addition of two veteran C-suite leaders to its team. Read the full press release here:
0
0
1
Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: https://t.co/jr3XrD8z6o
0
0
1
Join Westlake’s Mira Chaurushiya, Ph.D. and other biotech leaders on Tuesday, November 1 as they discuss this year’s turbulent market and what the future ahead might look like. Learn more about the topics and speakers here: https://t.co/jr3XrD8z6o
0
0
0
Congratulations to Mira Chaurushiya, PhD, Senior Partner at Westlake Village BioPartners, for making @BusinessInsider's list of the top 16 pioneers in biotech venture capital. Read the full article here: https://t.co/UGXOvUTjUC
0
0
1
Congratulations to @ArsenalBio! This Westlake-backed company will receive $70 million for a multi-year collaboration with @Genentech to advance next-generation cell therapies for cancer. Read the press release: https://t.co/2T9s65ziAN
0
0
1